328 related articles for article (PubMed ID: 36333710)
21. Timing and durability of response to erenumab in patients with chronic migraine.
Tepper SJ; Lucas S; Ashina M; Schwedt TJ; Ailani J; Scanlon J; Klatt J; Chou DE; Wang A; Paiva da Silva Lima G
Headache; 2021 Sep; 61(8):1255-1263. PubMed ID: 34363708
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
[TBL] [Abstract][Full Text] [Related]
23. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
[TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Ashina M; Tepper SJ; Brandes JL; Reuter U; Boudreau GP; Weatherall M; Gantenbein AR; Doležil D; Klatt J; Wang A; Karanam AK; Cheng S; Mikol DD
Headache; 2022 May; 62(5):624-633. PubMed ID: 35593783
[TBL] [Abstract][Full Text] [Related]
25. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
[TBL] [Abstract][Full Text] [Related]
27. Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series.
Silvestro M; Tessitore A; Scotto di Clemente F; Tedeschi G; Russo A
Headache; 2020 Jun; 60(6):1187-1195. PubMed ID: 32359106
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
29. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.
Ashina M; Dodick D; Goadsby PJ; Reuter U; Silberstein S; Zhang F; Gage JR; Cheng S; Mikol DD; Lenz RA
Neurology; 2017 Sep; 89(12):1237-1243. PubMed ID: 28835404
[TBL] [Abstract][Full Text] [Related]
30. Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study.
de Vries Lentsch S; Verhagen IE; van den Hoek TC; MaassenVanDenBrink A; Terwindt GM
Eur J Neurol; 2021 Dec; 28(12):4194-4203. PubMed ID: 34424593
[TBL] [Abstract][Full Text] [Related]
31. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
Pozo-Rosich P; Dolezil D; Paemeleire K; Stepien A; Stude P; Snellman J; Arkuszewski M; Stites T; Ritter S; Lopez Lopez C; Maca J; Ferraris M; Gil-Gouveia R
JAMA Neurol; 2024 May; 81(5):461-470. PubMed ID: 38526461
[TBL] [Abstract][Full Text] [Related]
32. A real-world, observational study of erenumab for migraine prevention in Canadian patients.
Becker WJ; Spacey S; Leroux E; Giammarco R; Gladstone J; Christie S; Akaberi A; Power GS; Minhas JK; Mancini J; Rochdi D; Filiz A; Bastien N
Headache; 2022 Apr; 62(4):522-529. PubMed ID: 35403223
[TBL] [Abstract][Full Text] [Related]
33. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
Eur J Neurol; 2022 May; 29(5):1505-1513. PubMed ID: 35098620
[TBL] [Abstract][Full Text] [Related]
34. Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis.
Fernández-Bravo-Rodrigo J; Cavero-Redondo I; Lucerón-Lucas-Torres M; Martínez-García I; Flor-García A; Barreda-Hernández D; Pascual-Morena C
Eur J Pharmacol; 2024 Aug; 976():176702. PubMed ID: 38823758
[TBL] [Abstract][Full Text] [Related]
35. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.
Ornello R; Baraldi C; Guerzoni S; Lambru G; Andreou AP; Raffaelli B; Gendolla A; Barbanti P; Aurilia C; Egeo G; Cevoli S; Favoni V; Vernieri F; Altamura C; Russo A; Silvestro M; Valle ED; Mancioli A; Ranieri A; Alfieri G; Latysheva N; Filatova E; Talbot J; Cheng S; Holle D; Scheffler A; Nežádal T; Čtrnáctá D; Šípková J; Matoušová Z; Casalena A; Maddestra M; Viola S; Affaitati G; Giamberardino MA; Pistoia F; Reuter U; Sacco S
J Headache Pain; 2022 Mar; 23(1):38. PubMed ID: 35305579
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
37. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
[TBL] [Abstract][Full Text] [Related]
38. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
Lipton RB; Tepper SJ; Reuter U; Silberstein S; Stewart WF; Nilsen J; Leonardi DK; Desai P; Cheng S; Mikol DD; Lenz R
Neurology; 2019 May; 92(19):e2250-e2260. PubMed ID: 30996060
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of erenumab in women with a history of menstrual migraine.
Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
[TBL] [Abstract][Full Text] [Related]
40. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
Overeem LH; Peikert A; Hofacker MD; Kamm K; Ruscheweyh R; Gendolla A; Raffaelli B; Reuter U; Neeb L
Cephalalgia; 2022 Apr; 42(4-5):291-301. PubMed ID: 34644203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
